Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Deals

PW Medtech Group Ltd Plans Independent Listing of Rekind Medtec on NEEQ to Boost Growth

Fineline Cube Jul 2, 2024

PW Medtech Group Ltd (HKG: 1358), a prominent medical device manufacturer based in China, is...

Company Drug

Innovent Biologics Presents Positive Phase I Results for IBI343 at ESMO GI Congress 2024

Fineline Cube Jul 2, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...

Company Medical Device

Ningbo-Based Jenscare Scientific Announces Successful Follow-up Data for Transjugular Tricuspid Valve Device

Fineline Cube Jul 2, 2024

Jenscare Scientific Co., Ltd (HKG: 9877), a leading manufacturer of structural heart disease devices headquartered...

Company Drug

Yantai Dongcheng Pharmaceutical’s 177LuLNC1011 Gets FDA Green Light for Prostate Cancer Clinical Trial

Fineline Cube Jul 2, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has...

Company Drug

SCG Cell Therapy Receives FDA Approval for HPV-Targeted SCG142 Clinical Trial

Fineline Cube Jul 2, 2024

SCG Cell Therapy Pte. Ltd, a Singapore-headquartered biotechnology company with a presence in Shanghai, has...

Company Drug

Boao Lecheng Approves Use of Sanofi’s Tzield as First-Line Therapy for Type 1 Diabetes Delay

Fineline Cube Jul 2, 2024

Tzield (teplizumab), recognized as the world’s first and only targeted therapy for delaying the onset...

Company Drug

Huadong Medicine’s ROR1-Targeting ADC HDM2005 Receives FDA Clinical Trial Approval

Fineline Cube Jul 2, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a pharmaceutical company based in China, has announced that...

Company Deals

Moon Biotech Secures Exclusive State-Owned Fund Investment in Series C+ Round

Fineline Cube Jul 2, 2024

Moon (Guangzhou) Biotech Co., Ltd, a leading microbiome platform company based in China, has reportedly...

Policy / Regulatory

China’s CDE Launches Pilot Program for Electronic Drug Registration Filings

Fineline Cube Jul 2, 2024

The National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) in China has issued...

Company Drug

China’s Sichuan Huiyu Pharmaceutical Halts Generic Cytosar Launch Following Strategy Review

Fineline Cube Jul 2, 2024

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a pharmaceutical company based in China, has announced...

Company Deals

China’s Henlius Biotech Partners with Sermonix for Japan Development of Breast Cancer Drug

Fineline Cube Jul 2, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a prominent biopharmaceutical company based in China, has announced...

Company Deals Medical Device

MicroPort Endovascular to Fully Acquire Optimum Medical Device in $65M Deal

Fineline Cube Jul 2, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading Chinese medical technology company, has...

Company Deals

Supercede Therapeutics Partners with Shanghai Universities for Anti-Tumor Cachexia Drug Developmen

Fineline Cube Jul 2, 2024

Fudan University and East China Normal University (ECNU) have entered into a global rights cooperation...

Company Drug

Eisai and Biogen Launch Alzheimer’s Drug Leqembi in China Following Market Approval

Fineline Cube Jul 1, 2024

Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, in partnership with Biogen Inc. (NASDAQ:...

Company Deals

Healthcare Firms Line Up for HKEX IPOs as Biotech Market Recovery Gains Momentum

Fineline Cube Jul 1, 2024

A number of healthcare companies are seeking to capitalize on the recovering market conditions by...

Company Drug

Hinova Pharmaceuticals’ HP518 Earns FDA Fast-Track Designation for AR+ Triple Negative Breast Cancer

Fineline Cube Jul 1, 2024

Hinova Pharmaceuticals (SHA: 688302), a biopharmaceutical company based in China, has announced that it has...

Company Drug

Jiangsu Hengrui’s Henagliflozin Gains Expanded Indication for Type 2 Diabetes Treatment in China

Fineline Cube Jul 1, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Drug

Gloria Bio’s Motixafortide Approved as Urgently Needed Import Drug by Hainan Medical Products Administration

Fineline Cube Jul 1, 2024

Guangzhou Gloria Biosciences Co., Ltd, a biopharmaceutical company based in China, has received approval from...

Company Deals Digital

Winning Health Partners with Unicom Digitization Medical to Boost Medical Industry Innovation

Fineline Cube Jul 1, 2024

Winning Health (SHE: 300253), a Shanghai-based company in the medical information industry, has entered into...

Company Drug

BeiGene’s Tislelizumab Approved by China’s NMPA for First-Line Extensive Stage Small Cell Lung Cancer

Fineline Cube Jul 1, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a biopharmaceutical company, has announced that its programmed-death...

Posts pagination

1 … 337 338 339 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.